Jonathan Hare

Jonathan is an accomplished R&D and global public health professional with over 15 years of expertise in translational biologics, vaccine development, and infectious disease research. 

Currently serving as a Translational Science Lead at the Francis Crick Institute, he plays a pivotal role in advancing research into tangible product development models, focusing on novel vaccine platforms, therapeutic antibodies, and diagnostic solutions.

Prior to this, he was Head of Immunology at Imophoron, a UK early-stage vaccine biotech company and prior to that was at IAVI, where amongst other programs he worked on developing clinical assays for their VSV-Lassa vaccine candidate and the PrEPVacc HIV Phase IIb study. 

His career also includes significant consultancy work, including advising on vaccine R&D capacity in Central and West Asia and supporting vaccine development. He is currently is a member of the WHO Technical Advisory Group on Combination Vaccines. 

Jonathan has a Ph.D. in Cancer Gene Immunotherapy from King’s College London and completed post-doctoral training at Louisiana State University Health Sciences Center in New Orleans.